Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Accumulated Expenses (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Accumulated Expenses for 8 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 14.98% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, down 14.98% year-over-year, with the annual reading at $1.7 million for FY2025, 14.98% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $1.7 million at Precision Biosciences, up from $1.3 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $6.8 million in Q4 2021, with the low at $656000.0 in Q1 2024.
  • Average Accumulated Expenses over 5 years is $3.0 million, with a median of $2.9 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses skyrocketed 215.18% in 2021, then tumbled 72.99% in 2022.
  • Over 5 years, Accumulated Expenses stood at $6.8 million in 2021, then crashed by 72.99% to $1.8 million in 2022, then skyrocketed by 172.47% to $5.0 million in 2023, then tumbled by 59.5% to $2.0 million in 2024, then fell by 14.98% to $1.7 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $1.7 million, $1.3 million, and $991000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.